Akebia Therapeutics Inc. (AKBA)
NASDAQ: AKBA
· Real-Time Price · USD
2.83
0.04 (1.43%)
At close: Sep 23, 2025, 3:59 PM
1.43% (1D)
| Bid | 2.78 |
| Market Cap | 750.36M |
| Revenue (ttm) | 203.73M |
| Net Income (ttm) | -36.48M |
| EPS (ttm) | -0.18 |
| PE Ratio (ttm) | -15.72 |
| Forward PE | 34.88 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.89 |
| Volume | 2,180,253 |
| Avg. Volume (20D) | 3,888,573 |
| Open | 2.79 |
| Previous Close | 2.79 |
| Day's Range | 2.78 - 2.90 |
| 52-Week Range | 1.24 - 4.08 |
| Beta | 1.02 |
| Ex-Dividend Date | n/a |
About AKBA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AKBA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AKBA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsAkebia Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-20.58%
Akebia Therapeutics shares are trading lower follo...
Unlock content with
Pro Subscription
4 months ago
+6.5%
Akebia Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
1 month ago · seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call TranscriptAkebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P...
